Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S6
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
38564707 (PubMed )
Supplement: cd-23-1217_supplementary_table_11_suppst11.pdf
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
Wu YL et al.
The Lancet. Oncology, 2024
Durable response to amivantamab in treatment refractory NSCLC harboring EGFR and complex MET mutations: A case report.
Schmalz L et al.
Lung Cancer (amsterdam, Netherlands), 2023
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target.
Spitaleri G et al.
Cancers, 2023
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
Yao Y et al.
Respiratory Research, 2023
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
Fujino T et al.
Journal of Hematology & Oncology, 2022
Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease.
Blaquier JB et al.
Drugs in Context, 2022
Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer.
Piper-Vallillo AJ et al.
Jto Clinical and Research Reports, 2020
Spectrum of Mesenchymal-Epithelial Transition Aberrations and Potential Clinical Implications: Insights From Integrative Pancancer Analysis.
Li J et al.
Frontiers in Oncology, 2020
Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
Cocco E et al.
Nature Medicine, 2019
31406350 (PubMed )
Supplement: NIHMS1533563-supplement-1.xlsx › Patient_3
Crizotinib-resistant MET mutations in gastric cancer patients are sensitive to type II tyrosine kinase inhibitors.
Shen B et al.
Future Oncology (london, England), 2019
Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.
Du J et al.
Oncotarget, 2017
28460431 (PubMed )
Supplement: oncotarget-08-26281-s001.pdf
Select a paper to view details